Medicamen Biotech enters into understanding with South African business conglomerate

10 Mar 2025 Evaluate

Medicamen Biotech (MBL) has entered into an understanding with a prominent South African business conglomerate for registering and marketing its products in the region. South Africa represents a $4 billion pharmaceutical market and is categorized as a regulated market.

The recent EU approval of MBL's plant has opened new avenues to explore such opportunities, aligning with the company's strategic vision of global expansion. The management is confident in leveraging this milestone to further strengthen its presence in regulated markets and drive future growth.

Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.

Medicamen Biotech Share Price

381.90 -8.35 (-2.14%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×